[Dimethylamino-[(2-oxo-1-pyridinyl)oxy]methylidene]-dimethylammonium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [Dimethylamino-[(2-oxo-1-pyridinyl)oxy]methylidene]-dimethylammonium
• 英文别名: [dimethylamino-(2-oxopyridin-1-yl)oxymethylidene]-dimethylazanium
• 化学式: C10H16N3O2+
• 分子量: 210.25
• InChiKey: VPMAWWKDEFLLBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds
  申请人：Pfizer Inc.

  公开号：US20140228356A1

  公开（公告）日：2014-08-14

  The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R 1 and R 2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐，其中该化合物具有如下式的结构， 变量R1和R2如规范中所定义。还披露了相应的药用组合物、治疗方法、合成方法和中间体。
• [EN] N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES<br/>[FR] N-[2-(2-AMINO-6,6-DISUBSTITUÉS-4,4A,5,6-TÉTRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL)-1,3-THIAZOL-4-YL]AMIDES
  申请人：PFIZER

  公开号：WO2017051276A1

  公开（公告）日：2017-03-30

  The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐，其中所述化合物具有式（I）的结构，变量R1、R2和R3如规范中所定义。还披露了相应的药用组合物、治疗方法、合成方法和中间体。
• Antibacterial amide macrocyles
  申请人：Lampe Thomas

  公开号：US20050256037A1

  公开（公告）日：2005-11-17

  The invention relates to antibacterial amide macrocycles and process for their preparation, their use for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially of bacterial infections.

  本发明涉及抗菌酰胺大环化合物及其制备方法，其用于治疗和/或预防疾病，以及其用于生产治疗和/或预防疾病的药物，特别是用于治疗细菌感染。
• NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
  申请人：Wakunaga Pharmaceutical Co., Ltd.

  公开号：EP3604305A1

  公开（公告）日：2020-02-05

  It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells. The present invention provides a pyridone carboxylic acid derivative represented by the following formula (1) or a salt thereof wherein R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 to R6 each represent a hydrogen atom or the like; R7 represents a hydrogen atom or the like; R8 represents a hydrogen atom, a halogen atom, the following formula (a) (wherein Ra1 and Ra2 each represent a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like, or R7 and R8 together represent =N-OR10 (wherein R10 represents a hydrogen atom, an optionally substituted lower alkyl group, or an aralkyl group), or R7 and R8 form an optionally substituted 4- to 6-membered saturated hetero ring together with the adjacent carbon atom, or the like; R9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.

  本发明旨在提供一种具有高抗肿瘤活性且对正常细胞毒性低的新型化合物。本发明提供了由下式（1）代表的吡啶酮羧酸衍生物或其盐 其中 R1 代表氢原子、卤素原子或类似物；R2 代表氢原子、卤素原子或类似物；R3 至 R6 各代表氢原子或类似物；R7 代表氢原子或类似物；R8 代表氢原子、卤素原子、下式（a）（其中 Ra1 和 Ra2 各自代表氢原子、羟基、任选取代的低级烷基或类似基团）或类似基团，或 R7 和 R8 共同代表 =N-OR10 （其中 R10 代表氢原子、任选取代的低级烷基或芳烷基），或 R7 和 R8 与相邻碳原子一起形成任选取代的 4 至 6 元饱和杂环，或类似基团；R9 代表氢原子或类似物；X 代表氮原子或类似物；Y 代表氮原子或类似物。
• METHOD FOR PRODUCING HAIRPIN SINGLE-STRAND RNA MOLECULES
  申请人：Toray Industries, Inc.

  公开号：EP3862431A1

  公开（公告）日：2021-08-11

  The present invention relates to a method for producing a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, comprising the step of reacting a first single-stranded oligo-RNA molecule represented by the following formula (I) with a second single-stranded oligo-RNA molecule represented by the following formula (II) in a mixed solvent comprising a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5'-Xc-Lx1 ... (I) and Lx2-X-Y-Ly-Yc-3' ... (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent comprising an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.

  本发明涉及一种生产能够抑制靶基因表达的发夹型单链 RNA 分子的方法，包括以下步骤： 在由缓冲溶液和亲水性有机溶剂组成的混合溶剂中，在脱水缩合剂存在的情况下，由下式 (I) 表示的第一单链寡核苷酸分子与由下式 (II) 表示的第二单链寡核苷酸分子反应： 5'-Xc-Lx1 ...... (I) 和 Lx2-X-Y-Ly-Yc-3' ...... (II) ，其中脱水缩合剂选自由三嗪类脱水缩合剂、脲类脱水缩合剂、脲类脱水缩合剂和脲类脱水缩合剂组成的组。...(I)和 Lx2-X-Y-Ly-Yc-3' ...(II)，其中脱水缩合剂选自由三嗪基脱水缩合剂、包含 N-羟基含氮芳香环结构的脲基脱水缩合剂、碳二亚胺基脱水缩合剂、2-卤代吡啶鎓基脱水缩合剂和甲脒基脱水缩合剂组成的组。